DOCSLIB.ORG

( 12 ) Patent Application Publication ( 10 ) Pub . No .: US 2020/0038330 A1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
( 12 ) Patent Application Publication ( 10 ) Pub . No .: US 2020/0038330 A1 US 20200038330A1 IN (19 ) United States ( 12) Patent Application Publication (10 ) Pub . No.: US 2020/0038330 A1 BARTHOLOMÄUS et al. (43 ) Pub . Date : Feb. 6 , 2020 (54 ) ABUSE - PROOFED ORAL DOSAGE FORM Publication Classification (51 ) Int. CI. ( 71) Applicant : GRÜNENTHAL GMBH , Aachen (DE ) A61K 9/20 ( 2006.01) ( 72 ) Inventors : Johannes BARTHOLOMÄUS , Aachen A61K 9/00 (2006.01 ) (DE ) ; Heinrich KUGELMANN , A61K 31/485 ( 2006.01) Aachen ( DE ) ; Elisabeth A61K 9/28 ( 2006.01) ARKENAU -MARIC , Köln (DE ) (52 ) U.S. CI. CPC A61K 9/2031 (2013.01 ) ; A61K 9/2068 (73 ) Assignee : GRÜNENTHAL GMBH , Aachen (DE ) ( 2013.01 ) ; A61K 9/0053 ( 2013.01) ; A61K 9/0002 ( 2013.01 ) ; A61K 31/485 (2013.01 ) ; (21 ) Appl. No.: 16 /542,808 A61K 9/28 (2013.01 ) ; A61K 9/2027 ( 2013.01) ; Aug. 16 , 2019 A61K 9/2893 (2013.01 ) ; A61K 9/2095 ( 22 ) Filed : ( 2013.01) ; A61K 9/2013 ( 2013.01 ) ; A61K Related U.S. Application Data 9/2054 ( 2013.01 ) (63 ) Continuation of application No. 15 /878,524 , filed on Jan. 24 , 2018 , now abandoned , which is a continu ation of application No. 15 /255,534 , filed on Sep. 2 , (57 ) ABSTRACT 2016 , now abandoned , which is a continuation of application No. 15 /059,730 , filed on Mar. 3 , 2016 , now abandoned , which is a continuation of applica The present invention relates to an abuse- proofed , oral tion No. 14 /795,900 , filed on Jul. 10 , 2015 , now dosage form with controlled opioid - release for once daily abandoned , which is a continuation of application No. administration , characterised in that it comprises at least one 13 /897,746 , filed on May 20 , 2013 , now abandoned , opioid with potential for abuse ( A ) , at least one synthetic or which is a continuation of application No. 10/890 , natural polymer ( C ) , optionally delayed - release matrix aux 763 , filed on Jul. 14 , 2004 , now abandoned . iliary substances , physiologically acceptable auxiliary sub stances ( B ), optionally a wax ( D ) and optionally at least one Foreign Application Priority Data delayed - release coating, component ( C ) or ( D ) in each case ( 30 ) exhibiting a breaking strength of at least 500 N , preferably Jul . 1 , 2004 (DE ) 10 2004 032 049.7 of at least 1000 N. US 2020/0038330 A1 Feb. 6 , 2020 1 ABUSE -PROOFED ORAL DOSAGE FORM [ 0007 ] The multilayer tablet disclosed in WO 95/20947 is [ 0001 ] This application is a continuation of U.S. patent based on a similar approach to preventing parenteral abuse , application Ser. No. 15 /878,524 , filed Jan. 24 , 2018, now said tablet containing the opioid with potential for abuse and pending , which is a continuation of U.S. patent application at least one gel former , each in different layers. Ser . No. 15 / 255,534 , filed Sep. 2 , 2016 , now abandoned , [0008 ] WO 03/015531 A2 discloses another approach to which is a continuation of U.S. patent application Ser . No. preventing parenteral abuse . A dosage form containing an 15 /059,730 , filed Mar. 3 , 2016 , now abandoned , which is a analgesic opioid and a dye as an aversive agent is described continuation of U.S. patent application Ser . No. 14 /795,900 , therein . The colour released by tampering with the dosage filed Jul. 10 , 2015 now abandoned , which is a continuation form is intended to discourage the abuser from using the ofU.S. patent application Ser. No. 13 /897,746 , filed May 20 , dosage form which has been tampered with . 2013 , now abandoned , which is a continuation of U.S. patent [ 0009 ] Another known option for complicating abuse application Ser. No. 10 /890,763 , filed on Jul . 14 , 2004 , now involves adding to the dosage form an antagonist to the abandoned , which claims priority of German Patent Appli opioid , such as for example naloxone or naltrexone , or cation No. 10 2004 032 049.7 , filed on Jul. 1 , 2004 , the compounds which cause a physiological defence response , entire contents of which patent applications are incorporated such as for example ipecacuanha ( ipecac ) root, or bitter herein by reference . substances . [ 0002 ] The present invention relates to an abuse -proofed oral dosage form with controlled opioid release for once [ 0010 ] However , since in most cases of abuse of dosage daily administration , comprising at least one opioid with forms with delayed - release of an opioid , it is still necessary potential for abuse ( A ) , at least one synthetic or natural to pulverise the dosage form , it was the object of the present polymer ( C ), optionally delayed -release matrix auxiliary invention to complicate or prevent the pulverisation preced substances, optionally physiologically acceptable auxiliary ing abuse of the dosage form comprising the means con substances (B ), optionally a wax ( D ) and optionally a ventionally available for potential abuse and accordingly to delayed - release coating, component ( C ) or ( D ) in each case provide a dosage form with controlled release of opioids exhibiting a breaking strength of at least 500 N , preferably with potential for abuse which ensures the desired therapeu of 1000 N. tic effect when correctly administered once daily , but from [ 0003] The name opioids is taken according to the inven which the opioids cannot be converted into a form suitable tion to mean compounds which interact with at least one for abuse simply by pulverisation . opioid receptor. In particular , with the exception of ( 1R2R ) [ 0011 ] This object was achieved by the preparation of the 3-( 3 -dimethylamino - 1 - ethyl- 2 -methyl - propyl ) phenol, the abuse -proofed oral dosage form , according to the invention , physiologically acceptable salts or derivatives thereof, opi with controlled release of at least one opioid for once daily oids are taken to mean those compounds which exhibit a administration , which dosage form comprises, in addition to potential for abuse . at least one opioid and / or at least one of the physiologically [ 0004 ] Preferably , opioids are used for combatting pain . acceptable compounds thereof , preferably salts or deriva To this end , analgesics are frequently used in long -term tives, preferably esters or ethers , with potential for abuse treatment, for example in the case of chronic pain or pain ( A ) , at least one synthetic or natural polymer ( C ) , optionally caused by tumours . In long - term treatment, in particular , it delayed - release matrix auxiliary substances , optionally is important to enable the patient to enjoy a good quality of physiologically acceptable auxiliary substances ( B ) , option life . The measures which improve the quality of life of a ally a wax (D ) , and optionally at least one delayed -release patient include dosage forms which allow once daily admin coating , component ( C ) or (D ) in each case exhibiting a istration . However, because of the relatively large quantity breaking strength of at least 500 N , preferably of 1000 N. of opioid , such dosage forms, which provide delayed release [0012 ] By using components ( C ) and optionally (D ) with of the active ingredient, are particularly attractive to the the stated minimum breaking strength , preferably in such abuser who wishes to induce the desired state of narcosis or quantities that the dosage form also exhibits such a mini euphoria as quickly as possible . mum breaking strength , pulverisation of the dosage form [0005 ] Since , however , delayed - release dosage forms con with conventional means and thus subsequent abuse , pref taining opioids with potential for abuse do not usually give erably nasal or parenteral abuse , may be complicated con rise to the kick desired by the abuser when taken orally even siderably or prevented . in abusively high quantities, these dosage forms for example in the form of tablets or capsules are also comminuted , e.g. [ 0013 ] Preferably , the components ( C ) and optionally ( D ) ground , and sniffed by the abuser for the purpose of abuse are present in such quantities that the dosage form exhibits or the active ingredients are extracted from the powder a breaking strength of at least 500 N , preferably of at least obtained in this way by means of an aqueous liquid and the 1000 N. resultant solution is administered parenterally , in particular [0014 ] Without sufficient comminution of the dosage intravenously , optionally after filtration through cotton wool form , non -hazardous parenteral, in particular intravenous or or cellulose wadding . This type of administration produces nasal administration is impossible or extraction of the active even more accelerated increase in opioid levels than with ingredient takes the abuser too long , or no or an inadequate oral or nasal abuse , with the result desired by the abuser, kick is obtained on abusive oral administration , since spon namely the “ kick ” or “ rush ” . taneous release does not occur. [ 0006 ] U.S. Pat . No. 4,070,494 proposed adding a [ 0015 ] According to the invention , comminution is taken swellable agent to the dosage form in order to prevent abuse . to mean pulverisation of the dosage form with conventional When water is added to extract the opioid , this agent swells means which are available to an abuser, such as for example and ensures that the filtrate separated from the gel contains a pestle and mortar, a hammer, a mallet or other usual means only a small quantity of active ingredient. for pulverisation by application of force . US 2020/0038330 A1 Feb. 6 , 2020 2 [0016 ] The dosage form according to the invention is thus ecarboxylate ) (pethidine ), phenadoxone, phenomorphane , suitable for preventing parenteral , nasal and/
Load more

Recommended publications
  • Capsicum Oleoresin and Homocapsaicin
    Printed on: Wed Jan 06 2021, 02:44:36 AM Official Status: Currently Official on 06-Jan-2021 DocId: 1_GUID-1560FD9B-BE0F-495E-9994-C5718733DB4C_2_en-US (EST) Printed by: Jinjiang Yang Official Date: Official as of 01-May-2019 Document Type: USP @2021 USPC 1 nordihydrocapsaicin, nonivamide, decanylvanillinamide, Capsicum Oleoresin and homocapsaicin. DEFINITION ASSAY Capsicum Oleoresin is an alcoholic extract of the dried ripe · CONTENT OF TOTAL CAPSAICINOIDS fruits of Capsicum. It contains NLT 6.5% of total Mobile phase: A mixture of acetonitrile and diluted capsaicinoids, calculated as the sum of capsaicin, phosphoric acid (1 in 1000) (2:3) dihydrocapsaicin, nordihydrocapsaicin, nonivamide, Standard solution A: 0.2 mg/mL of USP Capsaicin RS in decanylvanillinamide, and homocapsaicin, all calculated on methanol the anhydrous basis. The nonivamide content is NMT 5% of Standard solution B: 0.1 mg/mL of USP the total capsaicinoids, calculated on the anhydrous basis. Dihydrocapsaicin RS in methanol [CAUTIONÐCapsicum Oleoresin is a powerful irritant, and Sample solution: 5 mg/mL of Capsicum Oleoresin in even in minute quantities produces an intense burning methanol. Pass a portion of this solution through a filter of sensation when it comes in contact with the eyes and 0.2-µm pore size, and use the filtrate as the Sample solution. tender parts of the skin. Care should be taken to protect Chromatographic system the eyes and to prevent contact of the skin with (See Chromatography á621ñ, System Suitability.) Capsicum Oleoresin.] Mode: LC IDENTIFICATION
    [Show full text]
  • Alternative Formats If You Require This Document in an Alternative Format, Please Contact: [email protected]
    University of Bath PHD The extraction and chemistry of the metabolites of Mimosa tenuiflora and Papaver somniferum Ninan, Aleyamma Award date: 1990 Awarding institution: University of Bath Link to publication Alternative formats If you require this document in an alternative format, please contact: [email protected] General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal ? Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Download date: 23. Sep. 2021 THE EXTRACTION AND CHEMISTRY OF THE METABOLITES OF MIMOSA TENUIFLORA AND PAP AVER SOMNIFERUM. submitted by ALEYAMMA NINAN for the degree of Doctor of Philosophy of the University of Bath 1990 Attention is drawn to the fact that the copyright of this thesis rests with its author. This copy of the thesis has been supplied on condition that anyone who consults it is understood to recognise that its copyright rests with its author and that no quotation from the thesis and no information derived from it may be published without prior consent of the author.
    [Show full text]
  • Product Nutritional Analysis
    Product Nutritional Analysis CA Nutri Chemical Analysis Analysis Unit Price (ex VAT) SANAS Accredited? Lead Time Energy by Calculation kJ or kcal No charge if part of Full Nutri Carbohydrate by Calculation g/100g No charge if part of Full Nutri Moisture g/100g R 193 2 Ash g/100g R 193 3 Protein g/100g R 355 3 Glycaemic Carbohydrates g/100g R 1 649 5 Total Sugars g/100g R 1 088 5 (Glucose, Fructose, Sucrose, Lactose and Maltose) Total Fat by AOAC 996.06 g/100g R 950 7 Full Nutritional Fatty acid Composition by AOAC 996.06 g/100g R 1 087 Yes Label of which Saturated g/100g of which Monounsaturated g/100g of which Polyunsaturated g/100g Included as part of Fatty Acid 7 of which Trans Fatty Acids g/100g Composition Omega 3 mg/100g Omega 6 mg/100g Cholesterol mg/100g R 842 7 Total Dietary Fibre by AOAC 985.29 g/100g R 1 636 8 to 12 Sodium mg/100g R 529 5 Salt calculated from Sodium results g/100g No charge if Sodium requested Yes Salt Salt by chloride titration g/100g R 662 Yes 5 Acid Insoluble Ash g/100g R 390 5 to 7 Crude Fibre g/100g R 1 374 Yes 5 to 7 Water Activity - R 527 7 Other pH - R 150 2 Density g/ml R 133 Yes 3 Caffeine mg/100g R 705 Yes 5 Total Capsaicinoids mg/kg R 665 5 (Capsaicin, dihydrocapsaicin, nordihydrocapsaicin and Scoville Heat Value) Antimony (Sb) mg/kg R 813 Arsenic (As) mg/kg R 813 Subc to SGS 10 Calcium (Ca) mg/100g R 529 Chromium (Cr) mg/kg R 813 Copper (Cu) mg/kg R 529 Yes 5 to 7 Iron (Fe) mg/kg R 529 Yes 5 Inorganic Food Testing Potassium (K) mg/100g R 529 Yes 5 Phosphorus (P) mg/kg R 813 Subc 10 Selenium (Se)
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,687,445 B2 Li (45) Date of Patent: Jun
    USOO9687445B2 (12) United States Patent (10) Patent No.: US 9,687,445 B2 Li (45) Date of Patent: Jun. 27, 2017 (54) ORAL FILM CONTAINING OPIATE (56) References Cited ENTERC-RELEASE BEADS U.S. PATENT DOCUMENTS (75) Inventor: Michael Hsin Chwen Li, Warren, NJ 7,871,645 B2 1/2011 Hall et al. (US) 2010/0285.130 A1* 11/2010 Sanghvi ........................ 424/484 2011 0033541 A1 2/2011 Myers et al. 2011/0195989 A1* 8, 2011 Rudnic et al. ................ 514,282 (73) Assignee: LTS Lohmann Therapie-Systeme AG, Andernach (DE) FOREIGN PATENT DOCUMENTS CN 101703,777 A 2, 2001 (*) Notice: Subject to any disclaimer, the term of this DE 10 2006 O27 796 A1 12/2007 patent is extended or adjusted under 35 WO WOOO,32255 A1 6, 2000 U.S.C. 154(b) by 338 days. WO WO O1/378O8 A1 5, 2001 WO WO 2007 144080 A2 12/2007 (21) Appl. No.: 13/445,716 (Continued) OTHER PUBLICATIONS (22) Filed: Apr. 12, 2012 Pharmaceutics, edited by Cui Fude, the fifth edition, People's Medical Publishing House, Feb. 29, 2004, pp. 156-157. (65) Prior Publication Data Primary Examiner — Bethany Barham US 2013/0273.162 A1 Oct. 17, 2013 Assistant Examiner — Barbara Frazier (74) Attorney, Agent, or Firm — ProPat, L.L.C. (51) Int. Cl. (57) ABSTRACT A6 IK 9/00 (2006.01) A control release and abuse-resistant opiate drug delivery A6 IK 47/38 (2006.01) oral wafer or edible oral film dosage to treat pain and A6 IK 47/32 (2006.01) substance abuse is provided.
    [Show full text]
  • TRP Channel Transient Receptor Potential Channels
    TRP Channel Transient receptor potential channels TRP Channel (Transient receptor potential channel) is a group of ion channels located mostly on the plasma membrane of numerous human and animal cell types. There are about 28 TRP channels that share some structural similarity to each other. These are grouped into two broad groups: Group 1 includes TRPC ("C" for canonical), TRPV ("V" for vanilloid), TRPM ("M" for melastatin), TRPN, and TRPA. In group 2, there are TRPP ("P" for polycystic) and TRPML ("ML" for mucolipin). Many of these channels mediate a variety of sensations like the sensations of pain, hotness, warmth or coldness, different kinds of tastes, pressure, and vision. TRP channels are relatively non-selectively permeable to cations, including sodium, calcium and magnesium. TRP channels are initially discovered in trp-mutant strain of the fruit fly Drosophila. Later, TRP channels are found in vertebrates where they are ubiquitously expressed in many cell types and tissues. TRP channels are important for human health as mutations in at least four TRP channels underlie disease. www.MedChemExpress.com 1 TRP Channel Inhibitors, Antagonists, Agonists, Activators & Modulators (-)-Menthol (E)-Cardamonin Cat. No.: HY-75161 ((E)-Cardamomin; (E)-Alpinetin chalcone) Cat. No.: HY-N1378 (-)-Menthol is a key component of peppermint oil (E)-Cardamonin ((E)-Cardamomin) is a novel that binds and activates transient receptor antagonist of hTRPA1 cation channel with an IC50 potential melastatin 8 (TRPM8), a of 454 nM. Ca2+-permeable nonselective cation channel, to 2+ increase [Ca ]i. Antitumor activity. Purity: >98.0% Purity: 99.81% Clinical Data: Launched Clinical Data: No Development Reported Size: 10 mM × 1 mL, 500 mg, 1 g Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg (Z)-Capsaicin 1,4-Cineole (Zucapsaicin; Civamide; cis-Capsaicin) Cat.
    [Show full text]
  • Determination of Capsaicinoid Profile of Some Peppers Sold in Nigerian Markets
    Available online www.jocpr.com Journal of Chemical and Pharmaceutical Research, 2014, 6(4):648-654 ISSN : 0975-7384 Research Article CODEN(USA) : JCPRC5 Determination of capsaicinoid profile of some peppers sold in Nigerian markets 1N. C. Nwokem *, 2C. O. Nwokem, 2Y. O. Usman, 1O. J. Ocholi, 2M. L. Batari and 3A. A. Osunlaja 1Department of Chemistry, Ahmadu Bello University, Zaria, Nigeria 2National Research Institute for Chemical Technology, Zaria, Nigeria 3Umar Suleiman College of Education, Gashua, Nigeria ____________________________________________________________________________________________ ABSTRACT The capsaicinoid profile of six different peppers sold in Nigerian markets was determined by Gas Chromatography- Mass Spectrometry. The capsaicinoids were extracted from the peppers using methanol as extractant and analyzed without need for derivatization. A total of eight (8) capsaicinoids were identified and quantitated: Capsaicin, Dihydrocapsaicin Dihydrocapsaicin 1, Dihydrocapsaicin 2, Norcapsaicin, Nordihydrocapsaicin 1, Nordihydrocapsaicin 2 and Nornordihydrocapsaicin though, not fully present in all the varieties. Dihydrocapsaicin 1, Dihydrocapsaicin 2, Nordihydrocapsaicin 1, Nordihydrocapsaicin 2 and Nornordihydrocapsaicin are isomers. Seven were identified in the Cameroun pepper variety, six in “Zaria atarugu” and Miango, and five in each of the remaining varieties. In all the peppers analyzed, capsaicin had the highest relative concentration, which ranged from 27.3% in the Cameroun variety to 49.38% in the “Zaria atarugu” variety. The sum of the relative concentrations of capsaicin and dihydrocapsaicin ranged from 47.03% in the “Miango” variety to 87.3% in the “Zaria atarugu” variety. Keywords: Capsaicinoids, Gas Chromatography-Mass Spectrometry, Methanol, Pepper ____________________________________________________________________________________________ INTRODUCTION Peppers are widely used in many parts of the world as a result of their valued sensory attributes; colour, purgency and aroma.
    [Show full text]
  • Utilizing LC/UV and LC/MS for the Characterization, Isolation, And
    Utilizing LC/UV and LC/MS for the Characterization, Isolation, and Quantitation of Capsaicinoids in Chili Peppers and Hot Sauces J Preston, Seyed Sadjadi, Zeshan Aqeel, and Sky Countryman Phenomenex, Inc., 411 Madrid Ave., Torrance, CA 90501 USA PO19040114_W_2 PO14400613_W_2 Abstract Hot and spicy food has dramatically increased in popu- al different chili peppers and commercially available hot larity over the past 10-20 years. Capsaicin is the most sauces. Prep HPLC is then used to isolate individual cap- abundant compound found in chili peppers giving them saicinoids from the pepper extracts. Finally, a triple qua- their fiery flavor. Capsaicin is formed when vanillylamine druple MS system is employed to identify and quantitate is coupled to a 10 carbon fatty acid through an amide link- the observed capsaicinoids. age. However, there are other related compounds often called capsaicinoids. These compounds have the same Capsaicin was found to be the most prevalent capsaicinoid vanillylamine group but differ by the associated fatty acid species in all of the studied matrices. Significant amounts chain and are responsible for the perception of different of Nordihydrocapsaicin were found in a cayenne hot sauce heat profiles for different chili peppers. Some peppers are and in Thai chili pepper extract. Dihydrocapsaicin and Ho- described as having a high initial flash of heat while other modihydrocapsaicin were also identified in many of the in- peppers are described by a long and late burning profile. vestigated chili extracts and hot sauces but at lower levels. The typical concentration of these compounds were found The work presented here, initially uses HPLC with UV to be in the µg/g range but varied widely among the differ- detection to profile capsaicinoids extracted from sever- ent chili peppers and hot sauces.
    [Show full text]
  • Note: the Letters 'F' and 'T' Following the Locators Refers to Figures and Tables
    Index Note: The letters ‘f’ and ‘t’ following the locators refers to figures and tables cited in the text. A Acyl-lipid desaturas, 455 AA, see Arachidonic acid (AA) Adenophostin A, 71, 72t aa, see Amino acid (aa) Adenosine 5-diphosphoribose, 65, 789 AACOCF3, see Arachidonyl trifluoromethyl Adlea, 651 ketone (AACOCF3) ADP, 4t, 10, 155, 597, 598f, 599, 602, 669, α1A-adrenoceptor antagonist prazosin, 711t, 814–815, 890 553 ADPKD, see Autosomal dominant polycystic aa 723–928 fragment, 19 kidney disease (ADPKD) aa 839–873 fragment, 17, 19 ADPKD-causing mutations Aβ, see Amyloid β-peptide (Aβ) PKD1 ABC protein, see ATP-binding cassette protein L4224P, 17 (ABC transporter) R4227X, 17 Abeele, F. V., 715 TRPP2 Abbott Laboratories, 645 E837X, 17 ACA, see N-(p-amylcinnamoyl)anthranilic R742X, 17 acid (ACA) R807X, 17 Acetaldehyde, 68t, 69 R872X, 17 Acetic acid-induced nociceptive response, ADPR, see ADP-ribose (ADPR) 50 ADP-ribose (ADPR), 99, 112–113, 113f, Acetylcholine-secreting sympathetic neuron, 380–382, 464, 534–536, 535f, 179 537f, 538, 711t, 712–713, Acetylsalicylic acid, 49t, 55 717, 770, 784, 789, 816–820, Acrolein, 67t, 69, 867, 971–972 885 Acrosome reaction, 125, 130, 301, 325, β-Adrenergic agonists, 740 578, 881–882, 885, 888–889, α2 Adrenoreceptor, 49t, 55, 188 891–895 Adult polycystic kidney disease (ADPKD), Actinopterigy, 223 1023 Activation gate, 485–486 Aframomum daniellii (aframodial), 46t, 52 Leu681, amino acid residue, 485–486 Aframomum melegueta (Melegueta pepper), Tyr671, ion pathway, 486 45t, 51, 70 Acute myeloid leukaemia and myelodysplastic Agelenopsis aperta (American funnel web syndrome (AML/MDS), 949 spider), 48t, 54 Acylated phloroglucinol hyperforin, 71 Agonist-dependent vasorelaxation, 378 Acylation, 96 Ahern, G.
    [Show full text]
  • Capsicum Annum L.) in Southern USA
    ACTA AGRÍCOLA Y PECUARIA 6: E0061006 SCIENTIFIC ARTICLE https://doi.org/10.30973/aap/2020.6.0061006 (April 27, 2020) Effect of water stress on functional and marketable properties of roasted Big Jim chili pepper (Capsicum annum L.) in Southern USA Efecto del estrés hídrico en las propiedades funcionales y comerciales del chile rostizado Big Jim (Capsicum annum L.) en el sur de Estados Unidos Nancy Flores¹, Efrén Delgado¹, Stephanie Walker¹, Juan Rojas-Contreras², Gerardo Pámanes-Carrasco³* 1College of Agricultural, Consumer and Environmental Sciences, New Mexico State University, 1780 E University Ave, 88003, Las Cruces, New Mexico, United States of America. 2Instituto Tecnológico de Durango, Tecnológico Nacional de México, Boulevard Felipe Pescador #1830 Oriente, 34080, Durango, Durango, México. 3CONACYT-UJED, Instituto de Silvivultura e Industria de la Madera, Universidad Juárez del Estado de Durango, Boulevard Guadiana #501, Ciudad Universitaria, 34120, Durango, Durango, México. *Corresponding author: [email protected] Reception date: abstract January 19, 2020 This study aimed to evaluate the effect of water stress on spiciness, fatty acids, and aroma compound profile of roasted Big Jim chili. A flooded furrow irrigation system for chili Acceptance date: peppers production was utilized with 4 irrigation treatments: every 7, 9, 11, and 13 days March 18, 2020 for W1, W2, W3, and W4, respectively, in a completely randomized block design. Capsai- Online publication date: cinoid content was increased (~160%) by increasing water stress (P<0.05). However, the April 27, 2020 roasting process reduced the capsaicinoids content (P<0.05). Contents of linoleic, palmitic, and arachidonic acids were not affected. Water stress reduced hexanal and linalool content by approximately 64 and 72%, respectively (P<0.05), whereas 2-isobutyl-3-methoxypyrazi- ne content increased (P<0.05).
    [Show full text]
  • Biomolecules
    biomolecules Article Inhibitory Activity of Flavonoids, Chrysoeriol and Luteolin-7-O-Glucopyranoside, on Soluble Epoxide Hydrolase from Capsicum chinense Jang Hoon Kim and Chang Hyun Jin * Advanced Radiation Technology Institute, Korea Atomic Energy Research Institute, Jeongeup, Jeollabuk-do 56212, Korea; [email protected] * Correspondence: [email protected]; Tel.: +82-63-570-3162; Fax: +82-63-570-3159 Received: 5 December 2019; Accepted: 22 January 2020; Published: 24 January 2020 Abstract: Three flavonoids derived from the leaves of Capsicum chinense Jacq. were identified as chrysoeriol (1), luteolin-7-O-glucopyranoside (2), and isorhamnetin-7-O-glucopyranoside (3). They had IC values of 11.6 2.9, 14.4 1.5, and 42.7 3.5 µg/mL against soluble epoxide hydrolase 50 ± ± ± (sEH), respectively. The three inhibitors (1–3) were found to non-competitively bind into the allosteric site of the enzyme with K values of 10.5 3.2, 11.9 2.8 and 38.0 4.1 µg/mL, respectively. The i ± ± ± potential inhibitors 1 and 2 were located at the left edge ofa U-tube shape that contained the enzyme active site. Additionally, we observed changes in several factors involved in the binding of these complexes under 300 K and 1 bar. Finally, it was confirmed that each inhibitor, 1 and 2, could be complexed with sEH by the “induced fit” and “lock-and-key” models. Keywords: flavonoids; soluble epoxide hydrolase; non-competitive mode; induced fit; lock-and-key 1. Introduction Arachidonic acid is converted to epoxyeicosatrienoic acids (EETs) by cytochrome P450 epoxygenase [1]. EETs exist as four regioisomeric metabolites; 5,6-, 8,9-, 11,12- and 14,15-EETs [1].
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2009/0053319 A1 Perry (43) Pub
    US 2009.0053319A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0053319 A1 Perry (43) Pub. Date: Feb. 26, 2009 (54) SORE THROAT RELIEF COMPOSITION AND Publication Classification METHOD OF PRODUCING SAME (51) Int. Cl. A6II 3/165. (2006.01) (76) Inventor: Wye Jeffrey Perry, Albany, NY A6IPA6II 35/64II/00 (2006.01) (52) U.S. Cl. .......................... 424/537; 514/625; 514/627 Correspondence Address: (57)57 ABSTRACT AMIN HALLIHAN, LLC The present invention provides a sore throat relief composi 444 NORTHORLEANS STREET, SUITE 400 tion and a method of producing the composition comprising CHICAGO, IL 60654 (US) oleoresin capsicum containing capsaicin, dihydrocapsaicin, nordihydrocapsaicin, homodihydrocapsaicin, and homocap saicin as active ingredients, combined with vegetable glyc (21) Appl. No.: 11/842,458 erin, purified water, spearmint oil, wild cherry bark, clove honey, and ascorbic acid for fully relieving and preventing chronic and occasional Sore throat symptoms, including pain, (22) Filed: Aug. 21, 2007 dryness, and inflammation. US 2009/00533 19 A1 Feb. 26, 2009 SORE THROAT RELEF COMPOSITION AND drocapsaicin is an irritant and has a similar pungency to METHOD OF PRODUCING SAME capsaicin. Nordihydrocapsaicin, homodihydrocapsaicin, and homocapsaicinare also irritants and have a pungency of about FIELD OF THE INVENTION 8,600,000-9,100,000 Scoville units. 0001. The present invention relates to a sore throat relief 0003. Each capsaicinoid and its corresponding chemical composition containing natural capsaicinoids for relieving structure is shown below. Capsaicin H O Dihydrocapsaicin O Nordihydrocapsaicin O Homodihydrocapsaicin O N O Homocapsaicin H O Sore throat pain, dryness, and inflammation along with pro 0004 Capsaicinoids are irritants and produce a sensation viding antimicrobial properties.
    [Show full text]